S&P 500   4,128.89 (-0.84%)
DOW   34,036.05 (-0.35%)
QQQ   304.59 (-1.71%)
AAPL   152.03 (-1.69%)
MSFT   269.93 (+0.89%)
META   185.54 (-3.17%)
GOOGL   99.56 (-7.51%)
AMZN   100.11 (-1.96%)
TSLA   199.37 (+1.30%)
NVDA   225.27 (+1.60%)
NIO   10.69 (-2.11%)
BABA   105.76 (+0.25%)
AMD   85.71 (-0.23%)
T   19.09 (-0.83%)
F   13.47 (+0.15%)
MU   60.67 (-2.35%)
CGC   2.78 (-1.42%)
GE   81.95 (-0.19%)
DIS   111.41 (-0.20%)
AMC   5.76 (-6.80%)
PFE   43.87 (+0.64%)
PYPL   80.36 (-3.45%)
NFLX   361.88 (-0.29%)
S&P 500   4,128.89 (-0.84%)
DOW   34,036.05 (-0.35%)
QQQ   304.59 (-1.71%)
AAPL   152.03 (-1.69%)
MSFT   269.93 (+0.89%)
META   185.54 (-3.17%)
GOOGL   99.56 (-7.51%)
AMZN   100.11 (-1.96%)
TSLA   199.37 (+1.30%)
NVDA   225.27 (+1.60%)
NIO   10.69 (-2.11%)
BABA   105.76 (+0.25%)
AMD   85.71 (-0.23%)
T   19.09 (-0.83%)
F   13.47 (+0.15%)
MU   60.67 (-2.35%)
CGC   2.78 (-1.42%)
GE   81.95 (-0.19%)
DIS   111.41 (-0.20%)
AMC   5.76 (-6.80%)
PFE   43.87 (+0.64%)
PYPL   80.36 (-3.45%)
NFLX   361.88 (-0.29%)
S&P 500   4,128.89 (-0.84%)
DOW   34,036.05 (-0.35%)
QQQ   304.59 (-1.71%)
AAPL   152.03 (-1.69%)
MSFT   269.93 (+0.89%)
META   185.54 (-3.17%)
GOOGL   99.56 (-7.51%)
AMZN   100.11 (-1.96%)
TSLA   199.37 (+1.30%)
NVDA   225.27 (+1.60%)
NIO   10.69 (-2.11%)
BABA   105.76 (+0.25%)
AMD   85.71 (-0.23%)
T   19.09 (-0.83%)
F   13.47 (+0.15%)
MU   60.67 (-2.35%)
CGC   2.78 (-1.42%)
GE   81.95 (-0.19%)
DIS   111.41 (-0.20%)
AMC   5.76 (-6.80%)
PFE   43.87 (+0.64%)
PYPL   80.36 (-3.45%)
NFLX   361.88 (-0.29%)
S&P 500   4,128.89 (-0.84%)
DOW   34,036.05 (-0.35%)
QQQ   304.59 (-1.71%)
AAPL   152.03 (-1.69%)
MSFT   269.93 (+0.89%)
META   185.54 (-3.17%)
GOOGL   99.56 (-7.51%)
AMZN   100.11 (-1.96%)
TSLA   199.37 (+1.30%)
NVDA   225.27 (+1.60%)
NIO   10.69 (-2.11%)
BABA   105.76 (+0.25%)
AMD   85.71 (-0.23%)
T   19.09 (-0.83%)
F   13.47 (+0.15%)
MU   60.67 (-2.35%)
CGC   2.78 (-1.42%)
GE   81.95 (-0.19%)
DIS   111.41 (-0.20%)
AMC   5.76 (-6.80%)
PFE   43.87 (+0.64%)
PYPL   80.36 (-3.45%)
NFLX   361.88 (-0.29%)
NASDAQ:RCKT

Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

$20.24
-0.76 (-3.62%)
(As of 02/8/2023 12:39 PM ET)
Add
Compare
Today's Range
$19.96
$20.84
50-Day Range
$17.62
$22.76
52-Week Range
$7.57
$23.48
Volume
178,225 shs
Average Volume
764,374 shs
Market Capitalization
$1.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.75

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
161.9% Upside
$52.75 Price Target
Short Interest
Bearish
9.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.48mentions of Rocket Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.03) to ($3.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

345th out of 1,029 stocks

Pharmaceutical Preparations Industry

166th out of 504 stocks

RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Stock News Headlines

3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023 (RCKT)
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.
Elon Musk Claims Solar Will Soon Power the World
The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
Elon Musk Claims Solar Will Soon Power the World
The world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.
12 Cash-Rich Small Cap Stocks To Invest In
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings
11/03/2021
Today
2/08/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
151
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$52.75
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+160.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-169,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.05 per share

Miscellaneous

Free Float
50,201,000
Market Cap
$1.53 billion
Optionable
Optionable
Beta
1.23

Social Links


Key Executives

  • Gaurav D. ShahGaurav D. Shah
    Chief Executive Officer & Director
  • Kinnari Patel
    President & Chief Operating Officer
  • John C. Militello
    Treasurer, Chief Financial & Accounting Officer
  • Jonathan David Schwartz
    Chief Medical Officer & SVP-Clinical Development
  • Mayo Pujols
    Chief Technical Officer & Executive Vice President













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2023?

12 analysts have issued 1 year price targets for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they anticipate the company's stock price to reach $52.75 in the next year. This suggests a possible upside of 151.2% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 on January 1st, 2023. Since then, RCKT shares have increased by 7.3% and is now trading at $21.00.
View the best growth stocks for 2023 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.19. During the same period in the prior year, the business posted ($0.53) EPS.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.33%), Comerica Bank (0.38%), WCM Investment Management LLC (0.33%), Nisa Investment Advisors LLC (0.19%), Granite Point Capital Management L.P. (0.18%) and Synovus Financial Corp (0.17%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $21.00.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.59 billion. The biotechnology company earns $-169,070,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 151 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 2/8/2023 by MarketBeat.com Staff